Comparison of Antibody Immune Responses to Different HIV-1 Envelope Glycoprotein Mutants

Background: The identification of immunogens is crucial for human immunodeficiency virus type 1 (HIV-1) vaccine development. In our previous study, we demonstrated that HIV-1 envelope glycoprotein mutants based on the equine infectious anemia virus (EIAV) attenuated vaccine enhance immunogenicity, both for DNA immunization alone and as a combined DNA prime-vaccinia boost immunization. An RV144 clinical trial has demonstrated that an envelope protein boost may provide some degree of protection against HIV-1 infection. Keywords: HIV-1, mutant, vaccine, IgG subclass, prime-boost immunization.